Skip to main content
Equibles
JSPR logo

JSPR · Jasper Therapeutics, Inc.

Track JSPR — free

Use JSPR with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.70 +0.00 (+0.07%) At close · Aug 28
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$23.28M
Shares
33.27M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.70 Open$0.71 Day$0.66–0.71 52W close$0.34–2.84 Avg vol 30d786K Short int5.4M · 16.1% float · 7.8d Short vol51% Last earningsJun 12, 2026 DataJan 2024–Aug 2026 Filing10-Q · Aug 14

Raw chart and full-history price indicators begin at the captured split on Jan 4, 2024; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 14, 2026

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bearish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 14.4 · calm Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −37%
below
Price vs 50-day avg +8%
above
RSI (14) 48
neutral
MACD trend Negative
52-week position 14%
near low
Momentum
relative strength
Weak
1-month return +11%
trailing
6-month return −47%
trailing
YTD return −62%
this year
Relative strength −60%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-19% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.10% of float · ▲ +24.3% MoM · 7.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
52 holders — mid 3-yr range
Squeeze score 82
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 102%
annualized · 1-yr
Max drawdown −88%
past year
ATR 13.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−37% Bearish
Price vs 50-day avg
+8% Bullish
RSI (14)
48 Neutral
MACD trend
Negative Bearish
52-week position
14% Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-19% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.10% of float · ▲ +24.3% MoM · 7.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
52 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $1 · 14% Range high $3
vs 200-day avg -37% vs 50-day avg +8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
JSPR
Jasper Therapeutics, Inc.
this stock
$23.28M -61.8% — — 16.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +19.5% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.77B +2.9% +20.8% 19.7 2.3%
ARGX
Argenx SE
 $63.63B +21.7% — — 1.9%
CSLLY
Csl Ltd
 $59.23B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
52
% held
46.0%
Net QoQ
-3.7M sh
Top holder
Velan Capital Investment…
Held Float
View
Held by Funds
Fund positions
11
View
Short & Settlement
Short Interest Rising
Shares short
5.4M
Days to cover
7.8d
Change
+1.0M sh
View
Short Volume
Short vol %
51%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
15.2K
Value
$11.2K
As of
Jul 23, 2026
View
Off-Exchange
Off-exchange %
56.8%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-75.8M
EPS diluted
$-3.95
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 26, 2026
This year
18
View
Proposed Sales
Value
$20.2K
Shares
900
Filed
Dec 12, 2024
View
Exempt Offerings
Offering
$132.0M
Filed
Aug 5, 2026
View
Earnings & Events
Earnings Calls
Last call
Jun 12, 2026
View
Investor Relations
Latest news
Jasper Therapeutics Reports Secon…
Published
Aug 14, 2026
View

Performance

Raw-price comparisons begin at the captured split on Jan 4, 2024; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
JSPR -2.3% +11.1% -46.6% +11.1% -61.8%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY -2.8% +8.1% -60.0% +8.1% -74.6%
Key facts CIK 1788028 CUSIP 471871202 13F (30d) 52 filings 51 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)